GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rivalGlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. Marketed Share XGSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rivalhttps://pharmaphorum.com/news/gsk-kidney-disease-anaemia-drug-approved-in-japan-taking-on-astellas-rival/
FDA approves Kyowa Kirin’s new Parkinson’s drug NourianzThe FDA has approved a new drug for Parkinson’s disease, giving the nod to Kyowa Kirin’s Nourianz (istadefylline) Share XFDA approves Kyowa Kirin’s new Parkinson’s drug Nourianzhttps://pharmaphorum.com/news/fda-approves-kyowa-kirins-new-parkinsons-drug-nourianz/
Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006 Share XCould Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?https://pharmaphorum.com/news/could-kyowa-kirin-be-eyeing-ophthalmology-use-for-cancer-drug-tivozanib/
EU approves Kyowa Kirin’s drug for rare lymphomaThe European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is Share XEU approves Kyowa Kirin’s drug for rare lymphomahttps://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
NICE backs funding for Kyowa Kirin’s bone disorder drugChildren in England and Wales with a rare inherited disorder causing soft and weak bones can have access Share XNICE backs funding for Kyowa Kirin’s bone disorder drughttps://pharmaphorum.com/news/nice-backs-funding-for-kyowa-kirins-bone-disorder-drug/
